Entolimod is a clinical-stage immunotherapeutic designed to activate a well-characterized pathway in the innate immune system. Preclinical and clinical studies are evaluating its potential to modulate immune responses and support tissue recovery across high unmet-need indications.
Entolimod and its second-generation follow-on, Entolasta, together form a pipeline of innate immune modulating therapies being investigated across biodefense, oncology supportive care, and immuno-oncology. More than $140 million has been invested across the platform to date.
Velocity Bioworks provides process development, analytical services, and early-phase clinical drug substance manufacturing for biotech companies at its San Antonio facility.
Tivic Health received CE Mark approval for ClearUP Sinus Pain Relief, a handheld device using microcurrent waveform technology, for temporary sinus pain relief.
Valion Bio is a clinical-stage immunotherapeutics company working on issues ranging from cancer supportive care to national biodefense. It hires people who are rigorous, curious, and comfortable with the pace of multiple late-stage programs.
Tivic seeks to treat unmet medical needs with a dual platform approach to targeting the immune system. Tivic’s dual platform comprises biopharmaceutical treatments and a bioelectronic treatment, (i.e., a non-invasive vagus nerve stimulation device).
Tivic Health's website provides information about its proprietary microcurrent technology and allows users to purchase products and provide feedback. The company says it does not share personal information or use it for marketing without consent.
Valion Bio is advancing its compound **Entolimod** into a U.S. government-funded efficacy study for **gastrointestinal acute radiation syndrome (GI-ARS)** after demonstrating positive safety results. The **National Institute of Allergy and Infectious Diseases (NIAID)**-funded trial will assess Entolimod’s ability to improve survival rates and GI tissue recovery in radiation exposure cases. Top-line efficacy results are expected by **early December 2024**, marking a critical milestone for the company’s development pipeline.
Valion Bio reports no treatment-related toxicity from a single dose of **Entolimod** in a U.S. government-funded study by AFRRI. The findings support advancing to a fully funded therapeutic trial assessing **survival rates** and **gastrointestinal recovery** in radiation-exposed patients. The company develops biopharmaceuticals targeting radiation injury treatments.
Valion Bio receives unsolicited acquisition interest for its subsidiary, Velocity Bioworks, while evaluating strategic options to advance its lead drug candidate, entolimod, which targets innate immune pathways for cytoprotection and immune modulation. The company operates in the clinical-stage biopharmaceutical sector and is weighing potential pathways to maximize the asset’s value. Valion Bio is publicly traded on NASDAQ under the ticker VBIO.
Valion Bio’s interim CEO Dean Zikria outlines a 30-day plan focusing on advancing its lead asset **Entolimod** and the broader clinical pipeline. The agenda also includes commercializing **Velocity Bioworks** and exploring strategic opportunities to enhance the company’s integrated biologic development capabilities. The moves aim to drive progress in Valion’s clinical-stage programs.
Valion Bio validates LarmorBio’s BioScan-NMR™ platform, demonstrating its ability to monitor cell size, density, viability, and phenotype in real-time within bioreactors. The milestone confirms feasibility for continuous, non-invasive bioprocess tracking, achieved under an exclusive licensing agreement secured less than six months prior. This technology supports advanced biomanufacturing workflows by enabling precise, non-destructive analytics during production.